Q-omics provides the consensus-scored RNF148 profile across patient tissues and cancer cell-line models. RNF148 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNF148 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, RNF148 RNA expression shows 15,903 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRP, and LSCC as cancer lineages where RNF148 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF148 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF148 survival associations across molecular data types. RNF148 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF148 RNA expression–survival associations across cancer types. High RNF148 expression shows unfavorable associations in ACC, KIRP, TGCT and THYM, but favorable associations in OV and DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNF148 RNA expression.
This table summarizes RNF148 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNF148. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF148 shows lower tumor expression in KIRP, KIRC, LUSC, KICH and THCA and higher tumor expression in STAD. The KIRP box plot shows higher RNF148 RNA expression in normal versus tumor tissue (log2 FC = −0.401, t-test p < 0.001).
This table shows molecular features associated with RNF148 in patient tissues and cancer cell lines. In patient samples, RNF148 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF148 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
